Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
A transformative week brings Amgen’s landmark cardiovascular prevention data, Medicaid’s global pricing pivot, fierce obesity M&A competition, and expanding neuroscience approvals—while AI regulation and capital
Trump administration brokers obesity drug pricing pact with Novo and Lilly; FDA approves daratumumab for earlier-line myeloma; geopolitical tensions ease for Illumina while BD navigates
Market signals diverge as Charles River raises guidance while Bio-Techne misses; Eli Lilly’s expected weight-loss drug price cuts and medtech resilience add complexity to sector
November 5, 2025 Tuesday delivered a stark reminder of biotech’s unforgiving nature as Sarepta Therapeutics collapsed 40% following a devastating Duchenne muscular dystrophy confirmatory trial
Biotech opened the week navigating extreme regulatory volatility and clinical performance divergence. uniQure suffered a devastating 49% share collapse after the FDA reversed course on
Biotech delivered a sobering Halloween eve session as regulatory concerns collided with policy reforms and M&A speculation. Intellia Therapeutics’ CRISPR programs hit an FDA clinical
Healthcare markets delivered a news-heavy session today as mega-deals, regulatory shifts, and compelling clinical data converged to reshape sector dynamics. Thermo Fisher Scientific’s $8.9 billion
Monday delivered a mixed but ultimately positive session for healthcare investors, with strong pharmaceutical earnings and strategic deals offsetting concerns about biotech funding headwinds. Biopharma
Explore the latest biotech innovations from October 6-13, 2025: AstraZeneca’s oncology trials, FDA approvals for IPF and CSCC, allogeneic CAR-NK cells, and trends in direct-to-consumer
Genmab acquires Merus for $8B, FDA approves Alzheimer’s blood test, and Trump Administration secures drug pricing deals. Complete biotech industry analysis. 1. Genmab’s $8 Billion
